Described herein are methods and compositions for the use of treating and/or preventing vaginal bacterial infection and promoting healthy vaginal flora. Aspects of the invention relate to administering to a subject in need thereof a composition comprising a bacterial mixture of L. crispatus, L. gasseri, and L. jensenii.

The present disclosure discloses multifunctional lactobacilli capable of relieving a toxic effect of perfluorooctanoic acid (PFOA) and use thereof, and belongs to the technical field of microorganisms. Lactobacillus fermentum CCFM1051, Lactobacillus casei CCFM1052 and Lactobacillus buchneri CCFM1053 of the present disclosure have high adsorption effect on PFOA, can significantly relieve liver oxidative stress damage and serum biochemical indicators caused by PFOA, spleen atrophy caused by PFOA exposure, imbalance of intestinal microorganisms caused by PFOA exposure and metabolic disorder of intestinal flora caused by PFOA exposure, significantly increase the content of acetic acid and propionic acid in the intestinal tract, increase the fecal water content and decrease first black stool defecation time of mice with constipation, improve proliferation and MafA gene expression of INS-1 cells under high glucose, have the potential to relieve PFOA-related diabetes, reduce occurrence of liver diseases, metabolic diseases and potential carcinogenicity, and have broad use prospects.

The present invention in particular relates to the identification of novel Lactobacillus mudanjiangensis strains which are characterized in having a whole genome GC content of less than 43%. Moreover, these strains are characterized by the expression of a novel cellulase enzyme, which has numerous applications in the fields of for example agriculture, bioconversion, detergents, fermentation, food, paper industry, or textile industry.

The present disclosure relates to a strain of Lactobacillus sakei HEM224 (KCTC14065BP) and a composition for treating, preventing or alleviating inflammation or asthma, comprising the strain. A strain of Lactobacillus sakei HEM224 (KCTC14065BP) according to an embodiment of the present disclosure inhibits the production of pro-inflammatory factors, and exhibits an effect of treating asthma in an asthma animal model. Therefore, the strain can be applied to pharmaceutical compositions, food compositions, health functional food compositions and feed compositions for treating, preventing or alleviating inflammation or asthma.

The present invention relates to bacteria and metabolites thereof that are capable of binding to vaginal cells and producing hydrogen peroxide, their use in probiotic compositions and food products and methods for their selection. The invention also relates to the use of said bacteria, metabolites and probiotic compositions for the prevention and/or treatment of urogenital disorders.

The subject invention provides compositions and methods for treating human dermatological conditions by employing a microbiome-centered treatment approach. Preferred embodiments of the invention provide pharmaceutical and cosmetic compositions, and the methods of using the same, comprising a strain of Lactobacillus fermentum bacterium, or bioactive extracts thereof, derived from human microbiota and capable of growing in biofilm phenotype.

The present disclosure concerns a recombinant bacterial host cell capable of providing a nitrogen source to a yeast during fermentation to make ethanol. The recombinant bacterial host cell is capable of converting a biomass into ethanol. The recombinant bacterial host cell has at least one first genetic modification. The at least one genetic modifications confers to the recombinant bacterial host cell the ability to increase, when compared to a corresponding control bacterial cell lacking the at least one first genetic modification, the proteolytic activity associated with the recombinant bacterial host cell. The at least one genetic modification also confers the recombinant bacterial host cell the ability to provide a nitrogen source to a yeast capable of converting the biomass into ethanol, wherein the nitrogen source comprises a peptide, an amino acid and/or ammonia.

Disclosed herein is an isolated strain of Lactobacillus delbrueckii subsp. lactis LDL557, which is deposited at Deutsche Sammlung von Mikroorganismen and Zellkulturen GmbH under an accession number DSM 33617. Also disclosed herein are a composition including the isolated strain of Lactobacillus delbrueckii subsp. lactis LDL557, and use of the isolated strain of Lactobacillus delbrueckii subsp. lactis LDL557 for alleviating an inflammation-related disorder.

Provided in the present invention is a probiotic. The probiotic includes Parabacteroides distasonis with the microbial deposit number of CCTCC NO: M20222033, Limosilactobacillus fermentum with the microbial deposit number of CCTCC NO: M2023352, Lactobacillus salivarius with the microbial deposit number of CCTCC NO: M2023348, Enterococcus avium with the microbial deposit number of CCTCC NO: M2023350, and Bifidobacterium bifidum with the microbial deposit number of CCTCC NO: M2023349. The probiotic has good safety, has antioxidant activity, can inhibit pathogenic bacteria, can alleviate colon injury, can inhibit inflammation, and can alleviate diarrhea caused by chemotherapeutic drugs.

This invention relates to compositions comprising an effective amount of bacterial strains of the genera Lacticaseibacillus and Lactobacillus as well as methods and uses of said compositions for promoting growth and metabolism of vaginal Lactobacillus species in a subject in need thereof.